--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

The commitment to sustainability by Sanofi Canada has been hard to miss for anyone who’s visited the company’s 54-acre ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 21,865.00 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...